Business Context and Reporting Period
Company: Milestone Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 18, 2025
Reporting Period: Event date March 18, 2025
Business Context: The Company entered into an Amended and Restated Open Market Sale Agreement with Jefferies LLC to facilitate the sale of common shares.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. The financial metrics disclosed relate solely to the capital raising facility:
- Aggregate Offering Price: Up to $77,800,000.
- Previous Sales: Approximately $2.8 million sold under the original agreement prior to this amendment.
- Commission Rate: 3.0% of aggregate gross sales proceeds.
- Legal Expense Reimbursement Cap: $115,000 total ($75,000 for execution, $25,000 for Commission filings, $15,000 for other filings).
Material Changes Versus Prior Period
The primary material change is the amendment of the Open Market Sale Agreement originally dated July 29, 2020:
- Capacity Increase: The total offering capacity was increased to $77,800,000, inclusive of the $2.8 million previously sold.
- Agent Continuity: Jefferies LLC remains the sales agent.
- Terms: The agreement retains the "at the market" offering structure under Rule 415(a)(4) of the Securities Act of 1933.
Guidance, Outlook, and Risks
Management Commentary: The Company is not obligated to make any sales of Common Shares under the Amended Agreement. Sales will be made based on instructions from the Company regarding price, time, or size limits.
Outlook: The Company intends to file a prospectus supplement to its Form S-3 shelf registration statement (File No. 333-283162). The controlling provisions of the agreement will become effective upon the filing of this supplement.
Risks and Contingencies:
- Sales are subject to market conditions and Company discretion.
- The offering will terminate upon the sale of all shares or termination of the agreement per its terms.
- Offers are not valid in jurisdictions where such offers would be unlawful prior to registration.
Investor Verification Checklist
- Verify the filing of the Prospectus Supplement to Form S-3 (File No. 333-283162) to confirm the effective date of the agreement.
- Review the full text of the Amended and Restated Open Market Sale Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Monitor future 8-K filings or quarterly reports for actual sales volumes and proceeds generated under this facility.
- Confirm the Company's current cash position and burn rate to assess the necessity of utilizing this facility.